TSE:GUD Knight Therapeutics (GUD) Stock Price, News & Analysis C$8.63 +0.28 (+3.35%) As of 12:12 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Knight Therapeutics Stock (TSE:GUD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Knight Therapeutics alerts:Sign Up Key Stats Today's RangeC$8.38▼C$8.7050-Day RangeC$6.10▼C$8.3552-Week RangeC$5.65▼C$8.70Volume112,888 shsAverage Volume94,369 shsMarket CapitalizationC$846.22 millionP/E RatioN/ADividend YieldN/APrice TargetC$6.50Consensus RatingBuy Company Overview Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Read More Knight Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreGUD MarketRank™: Knight Therapeutics scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingKnight Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Downside RiskKnight Therapeutics has a consensus price target of C$6.50, representing about 24.7% downside from its current price of C$8.63.Amount of Analyst CoverageKnight Therapeutics has received no research coverage in the past 90 days.Read more about Knight Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Knight Therapeutics is -172.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Knight Therapeutics is -172.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioDue to a projected decrease in earnings for Knight Therapeutics, their PEG ratio cannot be calculated.Price to Book Value per Share RatioKnight Therapeutics has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for GUD. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKnight Therapeutics does not currently pay a dividend.Dividend GrowthKnight Therapeutics does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.02 News SentimentKnight Therapeutics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Knight Therapeutics this week, compared to 0 articles on an average week. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Knight Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders45.62% of the stock of Knight Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions23.49% of the stock of Knight Therapeutics is held by institutions.Read more about Knight Therapeutics' insider trading history. Receive GUD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GUD Stock News HeadlinesKnight Therapeutics Inc. (GUD:CA) Q1 2026 Earnings Call Transcript2 hours ago | seekingalpha.comKnight to Present at the 2026 Bloom Burton & Co. Healthcare Investor ConferenceApril 15, 2026 | markets.businessinsider.com"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and spotted Amazon when it was still considered a bookstore - moves followed by gains of 249,900%, 112,700%, and 216,100%. Now Gilder has identified three companies building a new chip architecture he calls the 'Trillion Dollar Triangle' - one that could make current AI data centers obsolete. One company designed it, one can build it at scale, and a third is preparing to go public.May 8 at 1:00 AM | Eagle Publishing (Ad)TSX Value Picks Knight Therapeutics And 2 Other Stocks Estimated Below Intrinsic ValueMarch 25, 2026 | uk.finance.yahoo.comKnight Therapeutics advances chronic GvHD expansion strategyFebruary 27, 2026 | finance.yahoo.com3 TSX Growth Companies With Insider Ownership As High As 27%January 28, 2026 | finance.yahoo.comProfound Medical Regains Exclusive Distribution Rights for TULSA-PRO(R) in Canada from KnightNovember 12, 2025 | barrons.comKnight Therapeutics Secures US$100 Million Credit Facility to Boost GrowthOctober 31, 2025 | msn.comSee More Headlines GUD Stock Analysis - Frequently Asked Questions How have GUD shares performed this year? Knight Therapeutics' stock was trading at C$6.05 at the start of the year. Since then, GUD shares have increased by 42.1% and is now trading at C$8.60. How were Knight Therapeutics' earnings last quarter? Knight Therapeutics Inc. (TSE:GUD) announced its quarterly earnings results on Thursday, May, 7th. The company reported $0.13 EPS for the quarter. The firm had revenue of $147.59 million for the quarter. Knight Therapeutics had a negative trailing twelve-month return on equity of 0.70% and a negative net margin of 1.19%. Read the conference call transcript. How do I buy shares of Knight Therapeutics? Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Knight Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Knight Therapeutics investors own include ARC Resources (ARX), Cenovus Energy (CVE), Enbridge (ENB), Whitecap Resources (WCP), Bombardier, Inc. Class B (BBD.B), Crescent Point Energy (CPG) and Suncor Energy (SU). Company Calendar Last Earnings5/07/2026Today5/08/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:GUD CIKN/A Webwww.gud-knight.com Phone514-484-4483FaxN/AEmployees725Year FoundedN/APrice Target and Rating Average Price Target for Knight TherapeuticsC$6.50 High Price TargetC$6.50 Low Price TargetC$6.50 Potential Upside/Downside-24.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)C($0.05) Trailing P/E RatioN/A Forward P/E Ratio85.19 P/E Growth-1013.5Net Income-C$30.73 million Net Margins-1.19% Pretax MarginN/A Return on Equity-0.70% Return on Assets0.51% Debt Debt-to-Equity Ratio10.15 Current Ratio2.39 Quick Ratio1.79 Sales & Book Value Annual SalesC$450.09 million Price / Sales1.87 Cash FlowC$2.24 per share Price / Cash Flow3.85 Book ValueC$7.74 per share Price / Book1.11Miscellaneous Outstanding Shares98,056,000Free FloatN/AMarket CapC$843.28 million OptionableNot Optionable Beta-0.21 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (TSE:GUD) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredMay 13: The Fed Shock is about to hit the marketsWall Street quantitative analyst Louis Navellier says a rare Federal Reserve regime change is opening a market...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GUD Stock Alerts